PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

methyldopa Side Effects

The reactions most often reported to the FDA for methyldopa (also sold as Aldomet), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

4,692
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of methyldopa come from 4,692 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 4,692 reports to the FDA Adverse Event Reporting System (FAERS) for methyldopa (Aldomet): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

4,692

Reports Mentioning Death

217

4.6% of reports — not proof the medicine caused the death

Hospitalizations

1,553

33.1% of reports

Top Indication

Hypertension

Most Reported Adverse Reactions

FOETAL EXPOSURE DURING PREGNANCY
1,261
PREMATURE BABY
888
MATERNAL EXPOSURE DURING PREGNANCY
794
EXPOSURE DURING PREGNANCY
654
PREMATURE DELIVERY
561
LOW BIRTH WEIGHT BABY
378
HYPERTENSION
255
FOETAL GROWTH RESTRICTION
200
DYSPNOEA
194
ATRIAL SEPTAL DEFECT
189
PRE-ECLAMPSIA
182
CAESAREAN SECTION
166
LIVE BIRTH
165
DRUG EXPOSURE DURING PREGNANCY
148
PATENT DUCTUS ARTERIOSUS
145
SMALL FOR DATES BABY
129
BLOOD PRESSURE INCREASED
126
HEADACHE
123

Who Reports Side Effects

Gender Distribution

Female 2,870 (74%)
Male 1,010 (26%)
Unknown 19

Age Distribution

0-17 361 (14%)
18-44 1,514 (57%)
45-64 352 (13%)
65-74 209 (8%)
75+ 236 (9%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 217 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
FOETAL EXPOSURE DURING PREGNANCY 61
PREMATURE BABY 34
DEATH 30
LOW BIRTH WEIGHT BABY 19
RESPIRATORY FAILURE 19
HYDROPS FOETALIS 15
CARDIAC ARREST 14
HYPERTENSION 13
PNEUMONIA 13
CARDIAC FAILURE 12
FOETAL GROWTH RESTRICTION 12
HYPOTENSION 12
MATERNAL EXPOSURE DURING PREGNANCY 12
ANAEMIA 11
NEUTROPENIA 11
PULMONARY HYPOPLASIA 11
RENAL FAILURE 11
THROMBOCYTOPENIA 11
CONGENITAL CYSTIC LUNG 10
FOETAL DEATH 10

Reactions in Hospitalization Reports

Top reactions in 1,553 reports where hospitalization was an outcome.

Reaction Reports
MATERNAL EXPOSURE DURING PREGNANCY 316
FOETAL EXPOSURE DURING PREGNANCY 218
PREMATURE BABY 197
EXPOSURE DURING PREGNANCY 196
PREMATURE DELIVERY 183
HYPERTENSION 152
DYSPNOEA 122
LIVE BIRTH 104
PRE-ECLAMPSIA 92
BLOOD PRESSURE INCREASED 86
ANXIETY 85
LOW BIRTH WEIGHT BABY 82
VOMITING 74
NAUSEA 68
PYREXIA 65
FOETAL GROWTH RESTRICTION 63
HEADACHE 62
CAESAREAN SECTION 59

Compare methyldopa vs acebutolol →

What the FAERS Data Reveals About methyldopa Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 4,692 voluntary reports linked to methyldopa and its brand equivalents (Aldomet), spanning 2004 through 2025. Of those, 217 (4.6%) listed death as an outcome and 1,553 (33.1%) involved hospitalization. The most common indication reported alongside adverse events was Hypertension.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 74% were female and 26% male; age distribution skews toward 18-44, with 1,514 reports in that bracket. The single most reported reaction is foetal exposure during pregnancy with 1,261 submissions, followed by premature baby and maternal exposure during pregnancy.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.